Subcutaneous Efgartigimod Expands Payer Potential For Argenx’s Drug

Offers gMG Patients Freedom From I.V. Treatment

With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.

Infusion of a hospital
argenx announced topline results for its subcutaneous formulation of efgartigimod • Source: Shutterstock

Only four months after approval of its intravenous drug Vyvgart (efgartigimod) for generalized myasthenia gravis (gMG), argenx N.V. is forecasting that the vast majority of patients who are candidates for treatment eventually may switch to the subcutaneous formulation after a successful Phase III clinical trial.

The company announced topline data on 22 March from the 110-patient ADAPT-SC study of subcutaneous efgartigimod in gMG, showing that...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category